Teva Pharmaceutical Industries (BSP:T1EV34) Construction In Progress: R$0 Mil (As of Mar. 2026)


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
11 GF Score
Price R$89.28
GF Value R$52.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Construction In Progress?

Teva Pharmaceutical Industries BSP:T1EV34 11 Construction In Progress is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:T1EV34 with a GF Score™ of 11/100 and a GF Value™ of R$52.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Teva Pharmaceutical Industries's quarterly construction in progress increased from Sep. 2025 (R$0 Mil) to Dec. 2025 (R$2,057 Mil) but then declined from Dec. 2025 (R$2,057 Mil) to Mar. 2026 (R$0 Mil).

Teva Pharmaceutical Industries's annual construction in progress increased from Dec. 2023 (R$6,992 Mil) to Dec. 2024 (R$8,114 Mil) but then declined from Dec. 2024 (R$8,114 Mil) to Dec. 2025 (R$2,057 Mil).

Teva Pharmaceutical Industries Construction In Progress Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Construction In Progress Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,847.17 6,289.24 6,992.02 8,114.33 2,056.80

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2,056.80 0.00
BSP:T1EV34
11GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of R$0 Mil mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Construction In Progress of R$0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Construction In Progress too high?
Teva Pharmaceutical Industries' current Construction In Progress is R$0 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Construction In Progress compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Construction In Progress of R$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Construction In Progress is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$52.51, compared to a current price of R$89.28 — trading 70% above its estimated fair value. The current Construction In Progress is R$0 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Construction In Progress is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$89.28 is trading 70% above its estimated GF Value™ of R$52.51. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for BSP:T1EV34:

  • Construction In Progress: R$0 Mil
  • GF Value™: R$52.51 vs. price of R$89.28 (70% above fair value)
  • GF Score™: 11/100 with 5 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
11GF Score

Get the complete analysis for BSP:T1EV34

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$89.28
Price
R$52.51
GF Value